Condition
Hemophilia A, Severe
Total Trials
7
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 7 trials
Late-Stage Pipeline
43%
3 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 3 (2)
P 4 (1)
Trial Status
Recruiting3
Unknown2
Active Not Recruiting1
Not Yet Recruiting1
Clinical Trials (7)
Showing 7 of 7 trials
NCT07414511Recruiting
Hemophilia A Research Program
NCT05817812Phase 3Active Not RecruitingPrimary
A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
NCT04817462Not ApplicableRecruiting
Liver Biopsy In Haemophilia Gene Therapy
NCT06738901Phase 3Not Yet RecruitingPrimary
An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients
NCT06320626Phase 4Recruiting
Pharmacokinetic-guided Dosing of Emicizumab
NCT05889754Unknown
Reliability and Validity of the Turkish Version of the PedHAL
NCT04754997Not ApplicableUnknownPrimary
Effect of Exercise in Pediatric Hemophilia
Showing all 7 trials